MP63-04 ONE YEAR ONCOLOGICAL OUTCOME UPDATED ANALYSIS OF a SINGLE-CENTER PROSPECTIVE, RANDOMIZED, CONTROLLED, NON-INFERIORITY TRIAL: EN BLOC VS. CONVENTIONAL TRANSURETHRAL RESECTION OF BLADDER TUMOR

Abstract

You have accessJournal of UrologyCME1 Apr 2023MP63-04 ONE YEAR ONCOLOGICAL OUTCOME UPDATED ANALYSIS OF a SINGLE-CENTER PROSPECTIVE, RANDOMIZED, CONTROLLED, NON-INFERIORITY TRIAL: EN BLOC VS. CONVENTIONAL TRANSURETHRAL RESECTION OF BLADDER TUMOR Pietro Diana, Andrea Gallioli, Angelo Territo, Óscar Rodriguez-Faba, Josep Maria Gaya, Francesco Sanguedolce, Jordi Huguet, Ruben Parada, Julia Aumatell, Alejandra Bravo, Ferran Algaba, Joan Palou, and Alberto Breda Pietro DianaPietro Diana More articles by this author , Andrea GallioliAndrea Gallioli More articles by this author , Angelo TerritoAngelo Territo More articles by this author , Óscar Rodriguez-FabaÓscar Rodriguez-Faba More articles by this author , Josep Maria GayaJosep Maria Gaya More articles by this author , Francesco SanguedolceFrancesco Sanguedolce More articles by this author , Jordi HuguetJordi Huguet More articles by this author , Ruben ParadaRuben Parada More articles by this author , Julia AumatellJulia Aumatell More articles by this author , Alejandra BravoAlejandra Bravo More articles by this author , Ferran AlgabaFerran Algaba More articles by this author , Joan PalouJoan Palou More articles by this author , and Alberto BredaAlberto Breda More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003321.04AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Several randomized controlled trials (RCTs) comparing en-bloc resection of bladder tumor (ERBT) versus conventional transurethral resection of bladder tumor (cTURBT) were published showing controversial results. In particular, 1-yr recurrence rate ranged from 5-40% and 11-31% for ERBT and cTURBT, respectively. We provide an updated analysis of an RCT comparing the oncological outcome of ERBT vs. cTURBT at 1-yr follow-up (FU). METHODS: This is an updated analysis of a single-center prospective, randomized, controlled, non-inferiority trial analyzing patients subjected to ERBT vs cTURBT for BC. Inclusion criteria were: tumor size of ≤3 cm, and ≤3 lesions, and no sign of muscle invasion and/or ureteral involvement. The trial (NCT04712201) was approved by the Institutional Review Board (2017/09c). Kaplan-Meier (KM) curves were used to illustrate recurrence-free survival. Log-rank test was used to assess univariable differences in recurrence-free survival/technique. RESULTS: From April 2018 to June 2021, 248 patients were assessed for eligibility. After excluding patients diagnosed with cT0/cT2/benign/variant histology (n=11/11/5/2), we relied on a cohort of 219 patients: 123 (56.2%) and 96 (43.8%) in the ERBT and cTURBT group. Patients presenting with low-grade (LG), high-grade (HG), and CIS were 70 (56.9%), 49 (39.8%), and 4 (3.3%) vs 56 (58.3%), 37 (38.5%), and 3 (3.1%) for ERBT versus cTURBT, respectively. 201 patients reached 1-yr FU. The median FU of patients without recurrence was 19mo (IQR 14-35). Bladder 1-yr recurrence was recorded in 11 (8.9%) cases in the ERBT group (5LG; 6HG) and 12 (12.5%) cases after cTURBT (5LG; 6HG), respectively. Median time to recurrence was 14 mo (IQR 8-22). The KM curve revealed that recurrence-free survival was similar between groups, as well as for LG/HG separately (p=0.88, 0.85, 0.98; Figure 1). CONCLUSIONS: No statistical difference was found in the comparison of recurrence rates between ERBT and cTURBT at 1-yr FU. Compared to other RCTs the heterogeneity in terms of bladder recurrence may be explained by the scarce and heterogenous adoption of tools and techniques proved to lower the recurrence rate of NMIBC, supporting the implementation of a TURBT-checklist. Source of Funding:- © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e872 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Pietro Diana More articles by this author Andrea Gallioli More articles by this author Angelo Territo More articles by this author Óscar Rodriguez-Faba More articles by this author Josep Maria Gaya More articles by this author Francesco Sanguedolce More articles by this author Jordi Huguet More articles by this author Ruben Parada More articles by this author Julia Aumatell More articles by this author Alejandra Bravo More articles by this author Ferran Algaba More articles by this author Joan Palou More articles by this author Alberto Breda More articles by this author Expand All Advertisement PDF downloadLoading ...